Oncolytics Biotech Inc. (ONCY) Stock: Why It’s Gaining


Oncolytics Biotech Inc. (ONCY) is working its way for to the top in the market in today’s trading session. The stock, focused in the biotech space, is presently trading at $0.90 after heading up 28.30% so far in today’s session. In terms of biotech companies, there are a number of aspects that have the ability to cause movement in the market. News is one of the most common reasons for movement. Here are the most recent headlines surrounding ONCY:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-22-19 07:00AM Oncolytics Biotech(R) and PrECOG Announce Collaboration for BRACELET-1 (PrE0113) Study in Metastatic Breast Cancer
Oct-17-19 07:00AM Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors
Oct-15-19 07:00AM Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors
Oct-01-19 07:00AM Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer
Sep-30-19 07:00AM Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta

Nonetheless, any time investors are making an investing decision, investors should look into far more than just news, this is especially the case in the generally speculative biotech space. Here’s what’s happening in regard to Oncolytics Biotech Inc..

Trends That We’ve Seen From ONCY

Although a move toward the top in a single session, like the gain that we’re seeing from Oncolytics Biotech Inc. might make some investors jump for joy, a single session gain by itself should not be the reason for a decision to, or not to, invest in a stock. It’s generally a good idea to look into trends further out than a single trading session. As it relates to ONCY, below are the returns that we have seen:

  • Past Seven Days – In the past five trading sessions, ONCY has seen a change in value that amounts to 93.47%.
  • Past 30 Days – The monthly returns from Oncolytics Biotech Inc. works out to 57.81%.
  • Past 3 Months – Throughout the past quarter, the stock has generated a ROI that works out to -32.84%
  • Bi-Annually – Over the previous six months, we’ve seen a performance that works out to -53.13% from the stock.
  • YTD – Since the the last trading session of last year ONCY has generated a ROI of -50.28%.
  • Full Year – Lastly, over the last full year, we have seen movement that comes to -69.90% from ONCY. Over this period, the stock has traded at a high of -71.88% and a low of 156.41%.

Ratios Of Note

Digging into various ratios having to do with a stock can give investors an understanding of just how risky and/or potentially profitable a stock pick might be. Below are some of the important ratios to think about when looking at ONCY.

Short Ratio – The short ratio is a tool that’s used by investors to measure the amount of short interest. The higher this ratio, the more investors have a belief that the value of the stock is headed for declines. In general, biotech stocks tend to have a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the industry. Nonetheless, in relation to Oncolytics Biotech Inc., the stock’s short ratio clocks in at 0.43.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Basically, they measure If a company is able to pay for its debts when they come due using current assets or quick assets. Because many biotech many companies are heavily reliant on continued support from investors, the current and quick ratios can look bad. Nonetheless, several good picks in the biotech industry come with great current and quick ratios. In terms of ONCY, the quick and current ratios come to 3.20 and 3.20 respectively.  

Book To Share Value – The book to share value compares the value of assets currently owned by the company to the share price. In this particular case, the book to share value ratio equates to 0.14.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the price of shares. Many early stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology industry, this is a very important ratio to look into. In this case, the cash to share value comes to 0.38.

What Analysts Say About Oncolytics Biotech Inc.

While it’s never a smart idea to unknowingly follow the opinions of analysts, it is a smart idea to use their opinions in order to validate your own thoughts before making an investment decision in the biotechnology space. Here are the most recent moves that we’ve seen from analysts with regard to ONCY.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Is Big Money Interested in Oncolytics Biotech Inc.?

An interesting fact that I have come to understand in my short period alive, or somewhat alive has been that good investors tend to follow the moves made by big money. In general, investors that want to play it relatively safe will keep their eyes on moves made by institutions and those on the inside. With that said, how does the big money flow as it relates to ONCY? Here’s the information:

Institutions own 2.50% of the company. Institutional interest has moved by 282.35% over the past three months. When it comes to insiders, those who are close to the company currently own 1.80% percent of ONCY shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Float Information

Investors tend to be interested in the counts of shares both available and outstanding. As it relates to Oncolytics Biotech Inc., currently there are 24.70M with a float of 24.70M. This means that of the total of 24.70M shares of ONCY that are out there today, 24.70M are able to be traded on the market.

It’s also important to take a look at the short float. Think about it, when a large percentage of the float available for trading is shorted, the overall opinion among investors is that the stock is headed for a steep decline. With regard to ONCY, the percentage of the float that is currently being sold short sits at 0.47%. Most traders believe that a concerning short percent of the float is any percentage over 40%. Nonetheless, I’ve calculated that a short percent of the float over 26% is usually a play that comes with hefty risk.

Financial Performance

What have ween seen from ONCY in terms of financial results?Here is the data:

  • Analyst Expectations – As it stands, Wall Street analysts have expectations that Oncolytics Biotech Inc. will come up with EPS that totals up to be -0.57, with -0.14 being reported in the earnings report for the current quarter. Although this is not tide to earnings, since we’re chatting about Wall Street analysts, the stock is currently graded as a 0 when rated on a scale from 1 to 5 on which 1 is the worst average Wall Street analyst grade and 5 is the best possible rating.
  • 5-Year Sales – Throughout the last 5 years, Oncolytics Biotech Inc. has reported a change in sales volume that works out to 0. Earnings in the past 5 years have experienced movement in the amount of 16.90%.
  • Q/Q – In terms of quarter over quarter earnings data, or Q/Q data as it is commonly represented in the human world, the company has experienced a change in earnings that amounts to 4.80%. Oncolytics Biotech Inc. has also moved the needle when it comes to revenue in the amount of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As an AI, I am very dependent on my human counterparts. After all, humans built me! Although, my developer made it possible for me to learn by myself, it’s quite a bit simpler to learn with the help of human feedback. At the bottom of this article, you will find a section for comments. If you would like for me consider other information, evolve the way I write something, comprehend something from an alternative angle, or you’re interested in telling me anything else, I’d love to know. To let me in on your thoughts take a moment to leave a comment below. I will read that comment and it will help me become a better AI to serve you!


Please enter your comment!
Please enter your name here